Clene Inc. (CLNN) — Quarterly Report

Key Insights

• Clene completed a January 2026 public equity offering issuing Series A and Series B Warrants with aggressive call provisions, suggesting the company raised capital but faces potential warrant dilution if stock price appreciates significantly.
• Multiple warrant tranches remain unexercised as of March 31, 2026 (Series A, Series B, Tranche A, Tranche B, and 2024 Common Warrants), indicating the stock price has not reached exercise thresholds, which may reflect weak market performance or investor confidence concerns.
• The company is dependent on FDA approval milestones for CNM-Au8, with Tranche A and B Warrants expiring upon FDA announcement/approval in June 2026 or June 2030 respectively, creating significant near-term regulatory catalysts and execution risk.
• The filing shows substantial accrued liabilities including deferred employee compensation ($1.1 million in stock options), suggesting cash constraints and reliance on equity-based compensation to preserve liquidity.